Shareholders Approve Reverse Merger with Clywedog Therapeutics
BRNS sits 26% above its 52-week low of $0.512 on elevated volume (2.0× avg).
Summary
Barinthus Biotherapeutics shareholders have approved the reverse merger with Clywedog Therapeutics, clearing a major hurdle for the strategic transaction.
Key Events · M&A and Partnerships · BRNS
-
Merger Approved by Shareholders
Shareholders voted overwhelmingly in favor of the Scheme of Arrangement and Scheme Implementation Proposal, with 99.98% approval at both the Court and General Meetings held on May 20, 2026.
-
Critical Step for Clywedog Merger
This approval is a key milestone in finalizing the reverse merger with Clywedog Therapeutics, as detailed in previous filings, including the DEFM14A on April 30, 2026.
-
Addresses Prior Challenges
The successful vote provides a path forward for the company, which recently faced a Nasdaq delisting notice and reported significant net losses in its 2025 10-K.
Analysis · BRNS · Life Sciences
Shareholders of Barinthus Biotherapeutics have overwhelmingly approved the Scheme of Arrangement and Scheme Implementation Proposal, which are critical steps to finalize the previously announced reverse merger with Clywedog Therapeutics. This approval removes a significant contingency for the merger, providing a clearer path forward for the company, especially in light of its recent Nasdaq delisting notice and financial challenges.
At the time of this filing, BRNS was trading at $0.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.1M. The 52-week trading range was $0.51 to $2.92. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.